Clinical trials recruiting for Metastatic Non-small Cell Lung Cancer (NSCLC)
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Imzokitug | 1 |
| Pumitamig | 1 |
| reICB regimen (NSCLC) | 1 |
| reICB regimen (melanoma) | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Georgia | 1 |
| Kentucky | 1 |
| Maryland | 1 |
| Mississippi | 1 |
| Nebraska | 1 |
| New York | 1 |
| Tennessee | 1 |
| Texas | 1 |
| Wisconsin | 1 |
Top cities
Self-screener
Recruiting trials
- A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
- Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade
Related conditions
Trials recruiting for Metastatic Non-small Cell Lung Cancer (NSCLC) often also study these conditions. Each links to its own recruiting-trial list.
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Metastatic Non-small Cell Lung Cancer (NSCLC) trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.